BDAZ, thanks for your links on Ossianix.  Looks to me from the MD&A that we will be doing a financing at these levels which will obviously be dilutive to one degree or another.  The share price slide tells me that someone(s) figured out that BTI would have to fund its' own human trials and have been selling off to either get in on the financing or buy back cheaper after the financing.  I guess the good news is that BTI's programs still seem to be on the right footing.